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Introduction
Proximal humeral fractures account for 5% to 6% of all adult fractures, with the majority occurring in people aged over 65 years 1 . Around half of these fractures are displaced (51%), with the majority involving the surgical neck 2 . Surgical treatment, either internal fixation or humeral head replacement, is being increasingly used 3, 4 . This has substantially contributed to the increased treatment costs for upper limb fractures 4 . The outcome following both surgical and non-surgical treatment of these fractures is frequently unsatisfactory 5 , with subsequent costs including those of revision and secondary surgery.
Given the established lack of evidence to conclude whether surgical intervention produces consistently better outcomes than non-surgical treatment for these fractures 5 , the Proximal Fracture of the Humerus Evaluation by Randomisation (PROFHER) trial was conducted to evaluate the clinical effectiveness and cost-effectiveness of surgery compared with nonsurgical treatment of the majority of displaced fractures of the proximal humerus involving the surgical neck in adults 6 .
Full details of the trial design and the clinical effectiveness results have been reported 7, 8 .
PROFHER recruited 250 adults with acute displaced fractures of the proximal humerus involving the surgical neck from the orthopaedic departments (fracture clinics or wards) of 32 acute care NHS hospitals between September 2008 and April 2011. The study inclusion and exclusion criteria are summarised in Table 1 . There was no statistically or clinically significant difference between surgical and non-surgical treatment in the primary outcome, the Oxford Shoulder Score (OSS) averaged over 2 years (0·75 points in favour of surgery, 95% CI -1·33 to 2·84; P = 0·48). There were no significant between group differences in secondary outcomes, including surgical or fracture related complications (30 of 125 in the surgical group versus 23 of 125 in the non-surgical group; P = 0·28); secondary surgery to shoulder (11 versus 11); increased or new shoulder related therapy (7 versus 4; P = 0·58); and mortality (9 versus 5; P = 0·27) 7 .
Despite the finding of a lack of clinical superiority of surgical treatment, it remains important to assess the relative healthcare costs of the two treatments over the two year period that also takes into account subsequent treatment and health-related quality of life. This study aimed to assess the cost-effectiveness of surgical versus non-surgical treatment for treating displaced fractures of the proximal humerus involving the surgical neck in adults, using individual patient data (IPD) from PROFHER.
Patients and methods
We performed a cost utility analysis where health related quality of life (HRQoL) was measured in terms of quality adjusted life years (QALYs), which represent years lived in perfect health. Costs and QALYs were evaluated on the basis of the NHS and Personal Social Services (NHS perspective) and expressed in UK pound sterling (GBP) at a 2012 price base. Costs and QALYs were discounted from year one at a rate of 3.5% in accordance to the current guidance 9 . The analysis was conducted on an intention-to-treat basis (ITT); thus the treatment groups were compared based on their initial random allocation irrespective of protocol deviations or withdrawal. The base-case analysis was conducted on a dataset generated by multiple imputation by chained equations [10] [11] [12] .
Sensitivity analyses included complete case (CC) analysis to test the impact of excluding patients with missing data on the final results. All analyses and modelling were conducted in Stata TM 12 (StataCorp LP, College Station, Texas, USA).
The mean age of the 250 trial participants was 66 years, range 24 to 92 years, and 192 (77%) were women. Patients were randomised on an equal basis to surgical or non-surgical treatment. The choice of surgical intervention was left to the treating surgeons, typically consultants, who used surgical interventions with which they were fully experienced. Nonsurgical treatment was initial sling-use. The measures taken to ensure comparability of good standard rehabilitation, are detailed elsewhere 13 . Trial participants were followed up for two years.
The PROFHER protocol 6 and all amendments were reviewed and approved by the York or Leeds (West) Research Ethics Committee (08/H1311/12). As detailed in the trial protocol 6 , cost and health outcome data were collected prospectively in parallel with the clinical outcomes. Data collection for cost outcomes was via hospital forms (baseline characteristics, details of surgery, inpatient stay, treatment confirmation at one month, physiotherapy and end of physiotherapy, one and two year follow-up) and patient questionnaires at 3, 6, 12 and 24 months; copies of these forms are available elsewhere 8 .
The main outcome for the economic analysis was QALYs based on the EQ-5D-3L TM (EuroQol Group, Rotterdam, The Netherlands) questionnaire reported by trial participants at baseline and subsequently. A prospective study assessing the validity of the EQ-5D for patients with proximal humeral fractures found the EQ-5D displayed good internal and external responsiveness and recommended its use as a quality of life measure in these patients 14 . In order to estimate utilities (HRQoL weights), and to reflect the preferences of the general UK population, the EQ-5D health states were valued using a UK-based social tariff 15 . QALYs were calculated by combining the utility estimates by the duration of time in each health state using the area under the curve method (AUC) 16 . Despite the randomisation process, which ensures that baseline variables are balanced between the arms of the trial, in practice (regardless of sample size) it is normal to find an imbalance in mean baseline utility.
As baseline utility is likely to be correlated with QALYs gained over time, there are robust reasons to control for baseline utility when estimating QALYs. Therefore the difference in mean QALYs between treatments groups was adjusted for baseline utility 17 .
Resource use related to the primary surgical intervention was collected using surgical forms completed by healthcare professionals present at each operation. These forms collected information on operation times, staff involved, the type of implant used, disposables required and whether there were any unexpected procedures during the intervention. Resource use after discharge was assessed using (i) patient questionnaires at 3, 6, 12 and 24 months to estimate visits to primary care professionals; and (ii) hospital forms at 1 and 2 years to estimate hospital visits, physiotherapy sessions and subsequent hospital treatment. The unit costs are presented in Table 2 . These were sourced from the Personal Social Services Research Unit 18 , Department of Health (NHS reference costs) 19 , hospitals (implant costs) and the British National Formulary 20 .
Complete case assessment excludes all patients with any missing or incomplete data.
Additional to the resulting sample usually being much reduced, complete case analysis might be biased if the data are not missing completely at random 21 . Thus incomplete data on costs and QALYs were imputed using multiple imputation (MI) with chain equations and predictive mean matching; which assumes that data are missing at random 22 . The same covariates applied in the primary effectiveness analysis were selected with stepwise regressions: EQ-5D TM , costs, treatment allocation, sex, age and tuberosity (involvement or not of either or both tuberosities). Rubin's rules were used to combine point and variance estimates across imputed datasets, allowing the estimation of difference in costs and QALYs between treatment groups 22 .
The base case analysis included only shoulder-related resource use. The cost-effectiveness of surgery was estimated by comparing mean adjusted incremental costs and QALYs between the two treatments groups in the trial at two years. The differences were estimated using seemingly unrelated regression (SUR) 23 . The incremental cost-effectiveness ratio (ICER) was estimated according to standard decision rules as the difference in mean total costs divided by the difference in mean total QALYs from baseline to two years. According to the National Institute for Health and Clinical Excellence (NICE) the current recommended threshold ranges between £20 000 -£30 000 per QALY 9 . Therefore if the estimated cost per QALY is below this threshold range, surgery would be considered to be cost-effective and its use in the NHS recommended. The ICER was re-expressed in terms of net monetary benefit (NMB) as an estimate of the gain (or loss) in resources of investing in this surgical intervention when those resources might be used elsewhere.
The uncertainty around the cost effectiveness results was explored by means of sensitivity analyses, all of which were controlled for covariates: (i) complete-case (CC) analysis ITT; (ii) MI and (iii) CC with inclusion of both shoulder and non-shoulder related resource use; and (iv) MI and (v) CC using patient questionnaires as the main source for estimating hospital visits and overnight stay. Non-parametric bootstrapping 24 was used to derive the cost effectiveness acceptability curves (CEAC) to express the probability that surgery is costeffective for the range of thresholds used by NICE.
RESULTS
Although a relatively high proportion (87% in each group) of patients returned their questionnaires at two years, the number of patients with complete follow-up assessments for all periods was much lower. A total of 173 (69%) patients -95 (76%) allocated surgery and 78 (62%) not surgery -comprised the complete case for utilities; i.e. data for all five EQ-5Ds dimensions were available for all five assessment time points. Complete data (both costs and utilities) were available for 54 (43%) patients allocated to surgery and 46 (37%) to nonsurgery. Fourteen patients died during the trial period, nine (7.2%) in the surgical arm and five (4.0%) in the non-surgical arm.
Patients in the surgery group had on average more outpatient appointments but fewer inpatient admissions (after their initial stay) than non-surgery group patients. The greater number of inpatient admissions in the non-surgery group reflected, in part, the finding that twice as many patients in this group were treated for newly diagnosed medical complications, such as cardiac or peripheral vascular events, compared with the surgical group (31 versus 15). The number of physiotherapy sessions received did not differ between treatment groups ( Table 3 ).
The resource use required for the surgical intervention was estimated in terms of the staff involved in the operation, the type of implant and disposables used and the length of stay. Of the 109 patients allocated surgery who received primary surgery, locking plates were used in 90 (82%) cases, hemiarthroplasty in 10 (9%) cases, intramedullary nails in 4 (4%) cases and other surgery in 5 (5%) cases. The mean operation time in theatre was 144 minutes. The mean average cost of surgery in the trial was £3053 per patient for an average length of stay of 3.8 nights in hospital. This is in accordance with NHS 2011-12 reference costs, which estimate a unit cost of £3550 (weighted by activity levels and adjusted using the elective to non-elective ratio) and an average length of stay of 3.8 nights for the selected Healthcare Resource Groups (HRGs) codes ( Table 1) .
A large portion of the cost associated with patients in the surgical group was attributable to the first three months of follow-up, inclusive of the costs of surgery (Table 3) . Thus, as expected, costs of surgery were the major cost driver for the surgery group. Conversely, hospital admissions were the main cost driver for the non-surgical group.
Patients in the surgery group started from a higher baseline utility on average (surgery 0·43 versus not surgery 0·38). However, at the end of the second year there was little difference in EQ-5D scores between treatment groups: surgery 0.67 versus not surgery 0.69 (Figure 1 ).
Patients allocated to non-surgery obtained on average a higher QALY gain than patients allocated to surgery. The difference in QALYs at two years (surgery -not surgery) when controlling for baseline utility (for available cases: 95 surgery versus 78 not surgery) was -0.066 (95% CI -0.186 to 0.054).
The incremental analysis (Table 4) shows that the surgical intervention cost on average £1758 more per patient when compared with non-surgical treatment (95% CI: £1126 to £2389). Patients in the surgical group accrued less QALYs than those for non-surgery both adjusting for covariates (-0·0101, 95% CI -0·13 to 0·11) or adjusting exclusively for baseline utility (-0·0158, 95% CI -0·13 to 0·10). Therefore the results indicate surgery was dominated by non-surgical intervention. Mean differences in both costs and QALYs were estimated with sampling uncertainty. As illustrated by the CEAC in Figure 2 , the probability of surgery being cost-effective was less than 10% given the NICE currently accepted threshold range of £20 000 to £30 000 per additional QALY.
The results of the five sensitivity analyses are presented in Table 4 . The base case analysis results were robust to the inclusion of all resource use (both shoulder and non-shoulder related) in the assessment: surgery remained a non-cost-effective intervention (MI dataset).
Although surgery did not represent a dominated option for the CC when including both shoulder and non-shoulder resource use, the ICER was higher than the thresholds that NICE normally consider for reimbursement decisions (£20 000 to £30 000 per QALY gained). The results were similar when we investigated the impact of using patient questionnaires (rather than hospital forms) as main source for resource use data.
DISCUSSION
The results of the study provide robust evidence that surgery was more costly from the NHS perspective and provided less health benefits compared with non-surgical treatment for the majority of patients with displaced proximal humeral fractures involving the surgical neck.
Given the uncertainty of the cost-effectiveness estimates it is unlikely that surgery represents an efficient intervention for the NHS, as the probability of surgery being cost-effective was 6% for the base case analysis. These results were robust to sensitivity analyses.
A key strength of our study is its pragmatic multicentre design, which has the advantage of reflecting actual practice in the UK hospitals thus providing timely and direct evidence of clinical and resource implications for the NHS. It should be highlighted that because of the pragmatic nature of the trial and the significant drawbacks of per protocol (PP) type analyses 25 , the base case used the ITT approach. Furthermore, PP analysis would not have been justified given the small number of cross-overs in the trial. A further strength is that the very detailed hospital forms designed for the trial, together with the multiple sources of cost data available for the analysis, allowed us to conduct an exhaustive micro costing exercise. This is core as it improved the accuracy of estimation of the cost associated to the treatment of proximal humeral fractures in an UK specific setting. Finally the use of QALYs, rather than any other clinical end point, provides evidence about the impact of this type of fracture on quality of life. The long-term consequences of proximal humeral fractures are reflected not only in shoulder function but in other domains of health as well. Using QALYs allows us to reflect the impact of fractures on whether individuals carry on with their usual activities or on their anxiety or depression levels, which are key to reflecting the benefits of any intervention related to its treatment. There is growing evidence that the EQ-5D is sensitive to changes in health status in older people with serious fractures 26 . Moreover, the internal and external responsiveness of the EQ-5D instrument has been positively validated in patients with proximal humeral fractures 14 ; therefore we can be confident that this instrument can capture small yet clinically important changes.
However, there are three potential limitations with the analysis of note. The first relates to the problem of missing data, which is a common issue in economic evaluations nested within clinical trials. Although the use of hospital forms rather than patient questionnaires helped to minimise the problem of incomplete data, missing data was a key determinant in our decisions of the best approach for our analysis. Despite the magnitude of missingness the results were robust to alternative assumptions on the pattern of missing data as illustrated by the complete case scenarios. Equally this did not change the outcome for cost-effectiveness.
It is therefore very unlikely that such assumptions regarding missing data will change the conclusions of our analysis. The second limitation relates to the duration of the study, as two years might still be considered too short in view of potential functional deterioration, with associated reduction in quality of life, and requirement for subsequent operations resulting from complications, such as avascular necrosis, that can occur or become symptomatic later on. It is notable, however, that the majority of complications occurred in the first year. Furthermore the HRQoL observed over the study, which shows little difference between the two groups in overall mean QALYs (Figure 1 ), also suggests that it is unlikely that any important difference in QALYs would emerge beyond the trial follow-up. These results are supported by the lack of clinically or statistically differences between surgical and nonsurgical treatment, either overall or at individual time points (at 6, 12 and 24 months) for the Oxford Shoulder Score (primary outcome of the trial) or any other secondary outcome 7 .
Finally, as per the cost-effectiveness analysis plan, we did not undertake pre-specified subgroup analysis by age or fracture type because no clinically important subgroup effect emerged from the trial. Nonetheless, given age and fracture type were included as covariates in the model, the results already capture the impact they might have on the costeffectiveness of surgical treatment.
To the best of our knowledge there is very little evidence regarding the cost-effectiveness of surgery for the treatment of proximal humeral fractures. Fjalestad et al 27 From this analysis we conclude that surgery is not cost-effective compared with providing non-surgical treatment. The NMB associated with surgery was negative, indicating that the resources to be displaced would be greater than the benefit to be gained if surgery was implemented in the NHS. However, there is a trend of increased surgery among patients with displaced proximal humeral fractures involving the surgical neck. In terms of policy implications disinvesting in existing non cost-effective interventions will give the opportunity to invest NHS resources elsewhere. In England there were 3,519 first listed consultant episodes for people with proximal humeral fractures involving an operation during 2011/12. If we assume, based approximately on fracture epidemiology 2 , that around 80% of these were displaced fractures involving the surgical neck then the annual cost saving to NHS England from not operating on half of the people with the trial fractures would be around £2.5 million.
The evidence presented here relates to surgery conducted in the UK. Inevitably different economic parameters will apply in other countries, which limits the generalisability of our results 28 . However, given the similarities in the choice of implants and surgical procedures in many other countries, we suggest these results are more generally applicable.
Future research on costs and outcomes would strengthen the results of the current economic evaluation. To this end, a long term follow-up of the PROFHER trial is already ongoing, with 80% of the trial participants giving their consent to be followed up at 3, 4 and 5 years. This will allow us to explore how the cost-effectiveness of surgery compared with nonsurgical treatment evolves over time. In case any potential benefit is found, the extrapolation of economic outcomes over a lifetime period will be considered. 54.08 (*) All manufacturer prices were provided by hospitals. Five different types of plates and screws provided by different manufacturers were used in the trial: PHILOS (Synthes), AXSOS (Stryker), S3 Plate (DePuy), Polarus PHP (Acumed) and NCB plate (Zimmer). Costs
